BioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by GW&K Investment Management LLC

GW&K Investment Management LLC decreased its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 16.2% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,197,765 shares of the biotechnology company’s stock after selling 425,772 shares during the period. GW&K Investment Management LLC owned 1.04% of BioCryst Pharmaceuticals worth $16,681,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in BCRX. Farther Finance Advisors LLC grew its stake in BioCryst Pharmaceuticals by 326.8% during the third quarter. Farther Finance Advisors LLC now owns 10,590 shares of the biotechnology company’s stock worth $80,000 after buying an additional 8,109 shares during the period. Vestmark Advisory Solutions Inc. acquired a new stake in BioCryst Pharmaceuticals during the 3rd quarter valued at $81,000. State of Alaska Department of Revenue purchased a new stake in BioCryst Pharmaceuticals during the 3rd quarter worth $90,000. MQS Management LLC purchased a new stake in BioCryst Pharmaceuticals during the 3rd quarter worth $99,000. Finally, Inceptionr LLC acquired a new position in BioCryst Pharmaceuticals in the 2nd quarter worth $107,000. 85.88% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, insider Alane P. Barnes sold 21,773 shares of the firm’s stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $7.65, for a total transaction of $166,563.45. Following the transaction, the insider owned 398,751 shares in the company, valued at $3,050,445.15. This trade represents a 5.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 5.10% of the stock is owned by company insiders.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX opened at $8.48 on Friday. BioCryst Pharmaceuticals, Inc. has a 12 month low of $6.00 and a 12 month high of $11.31. The stock has a fifty day moving average price of $7.23 and a 200 day moving average price of $7.41. The company has a market cap of $2.13 billion, a P/E ratio of 7.07 and a beta of 0.74.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Thursday, February 26th. The biotechnology company reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.07 by $1.05. The company had revenue of $163.28 million during the quarter, compared to the consensus estimate of $151.32 million. BioCryst Pharmaceuticals had a net margin of 30.16% and a negative return on equity of 84.33%. The company’s revenue for the quarter was up 209.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.13) earnings per share. As a group, research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.

Analyst Ratings Changes

BCRX has been the topic of a number of recent analyst reports. HC Wainwright upped their target price on BioCryst Pharmaceuticals from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Monday, December 15th. Weiss Ratings upgraded shares of BioCryst Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a research note on Wednesday. Evercore began coverage on shares of BioCryst Pharmaceuticals in a report on Wednesday, February 18th. They set an “outperform” rating and a $17.00 price objective for the company. Finally, Royal Bank Of Canada dropped their target price on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating for the company in a research report on Friday, January 30th. Ten equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $19.64.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.